CYRIA and glioblastoma: By employing a multi-step selection criterion, we identify a novel hypomethylation signature for GBM prognostication, which comprises of three CpGs interrogated on both Infinium 27 k and 450 k platforms: cg23855093 (GPR128), cg13997435 (S100A2) and cg10106284 (FAM49A) (Figure 1C).